Minireviews
Copyright ©The Author(s) 2019.
World J Gastroenterol. Jan 7, 2019; 25(1): 69-84
Published online Jan 7, 2019. doi: 10.3748/wjg.v25.i1.69
Figure 1
Figure 1 Recommendation for the management of medication based on current studies. 1During the first 30 d following coronary stenting and during the first 90 d following acute coronary syndrome; 2The influence of short-term discontinuation has not been determined; 3Aspirin should be continued; 4Resumption reduces cardiovascular events but may increase rebleeding; 5The influence of long-term discontinuation has not been determined; 6Changing to apixaban, or reducing the dose of dabigatran to 110 mg b.i.d may reduce rebleeding in GIB patients taking warfarin, dabigatran (150 mg b.i.d) or rivaroxaban. NSAIDs: Nonsteroidal anti-inflammatory drug; DOAC: Direct-acting oral anticoagulant; PT-INR: Prothrombin time-international normalized ratio.